At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $238.87, up 0.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALNY shares have lost -2.61% over the last week, with a monthly amount glided 1.96%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on November 12, 2024, when Wolfe Research downgraded its rating to a Underperform. On August 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $370 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $173 on February 16, 2024. Wolfe Research initiated its recommendation with a Peer Perform. Wells Fargo started tracking with a Equal Weight rating for this stock on December 08, 2023, and assigned it a price target of $171. In a note dated December 08, 2023, Wells Fargo initiated an Equal Weight rating.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $310.6 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $238.87 at the most recent close of the market. An investor can expect a potential return of 30.03% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.09B for trailing twelve months, which represents an -33.26% plunge. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 3.24 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 31.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 233.90 points at the first support level, and at 228.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 243.36, and for the 2nd resistance point, it is at 247.84.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.75. In addition, the Quick Ratio stands at 2.69 and the Cash Ratio stands at 0.9. Considering the valuation of this stock, the price to sales ratio is 14.71, the price to book ratio is 951.22.
Transactions by insiders
Recent insider trading involved Garg Pushkal, CMO & EVP Dev & Med Affairs, that happened on Dec 12 ’24 when 1752.0 shares were sold. Officer, Garg Pushkal completed a deal on Dec 12 ’24 to buy 1752.0 shares. Meanwhile, Chief Executive Officer Greenstreet Yvonne sold 5219.0 shares on Nov 26 ’24.
